Cannabinoid-Based Ocular Therapies and Formulations

The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid-based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided.

[1]  S. Majumdar,et al.  Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure in Normotensive Dutch-Belted Rabbits , 2022, Pharmaceutics.

[2]  Huifang Zhou,et al.  Immune modulating nanoparticles for the treatment of ocular diseases , 2022, Journal of Nanobiotechnology.

[3]  Farhang Modaresi,et al.  The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes , 2022, Pharmaceutical Medicine.

[4]  L. Phillips,et al.  The value of real world evidence: The case of medical cannabis , 2022, Frontiers in Psychiatry.

[5]  R. B. Walker,et al.  Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery , 2022, International journal of molecular sciences.

[6]  M. S. Akhtar,et al.  Development of cannabidiol nanoemulsion for direct nose to brain delivery: statistical optimization, in vitro and in vivo evaluation , 2022, Biomedical materials.

[7]  C. Brullo,et al.  Nanotechnology for Pediatric Retinoblastoma Therapy , 2022, Pharmaceuticals.

[8]  A. Hoffman,et al.  Strategies for enhancing the oral bioavailability of cannabinoids , 2022, Expert opinion on drug metabolism & toxicology.

[9]  P. Couvreur,et al.  Micro- and Nanocarriers for pain alleviation. , 2022, Advanced drug delivery reviews.

[10]  Bryan M. Williams,et al.  Automatic detection of glaucoma via fundus imaging and artificial intelligence: A review , 2022, Survey of ophthalmology.

[11]  S. Benita,et al.  The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure. , 2022, International journal of pharmaceutics.

[12]  Sumeet Gupta,et al.  Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy—An Overview on Recent Advances , 2022, Pharmaceutics.

[13]  S. Majumdar,et al.  Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits. , 2022, International journal of pharmaceutics.

[14]  K. Swindle-Reilly,et al.  Considerations for Polymers Used in Ocular Drug Delivery , 2022, Frontiers in Medicine.

[15]  J. Álvarez-Fuentes,et al.  Receptor-targeted nanoparticles modulate cannabinoid anticancer activity through delayed cell internalization , 2022, Scientific reports.

[16]  H. Turner,et al.  Potential Use for Chronic Pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) Nanoparticles Enhance the Effects of Cannabis-Based Terpenes on Calcium Influx in TRPV1-Expressing Cells. , 2022, International journal of pharmaceutics.

[17]  E. Messmer Pathophysiology of dry eye disease and novel therapeutic targets. , 2022, Experimental eye research.

[18]  M. Cordeiro,et al.  VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma , 2022, Acta ophthalmologica.

[19]  A. Camins,et al.  Lipid Nanoparticles for the Posterior Eye Segment , 2021, Pharmaceutics.

[20]  U. Gehlsen,et al.  Topical application of cannabinoid-ligands ameliorates experimental dry-eye disease. , 2021, The ocular surface.

[21]  A. Rodrigues,et al.  Pickering emulsions stabilized with chitosan/collagen peptides nanoparticles as green topical delivery vehicles for cannabidiol (CBD) , 2021, Colloids and Surfaces A: Physicochemical and Engineering Aspects.

[22]  Qipeng Yuan,et al.  Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy , 2021, Particuology.

[23]  A. Sosnik,et al.  Cannabidiol-Loaded Mixed Polymeric Micelles of Chitosan/Poly(Vinyl Alcohol) and Poly(Methyl Methacrylate) for Trans-Corneal Delivery , 2021, Pharmaceutics.

[24]  B. Rebesco,et al.  Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case , 2021, Healthcare.

[25]  G. Ousler,et al.  Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study , 2021, Ophthalmology and Therapy.

[26]  A. Hauser,et al.  Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development , 2021, Frontiers in Medicine.

[27]  J. Crecente‐Campo,et al.  Nanotechnologies for the delivery of biologicals: historical perspective and current landscape. , 2021, Advanced drug delivery reviews.

[28]  R. Löbenberg,et al.  Development of a novel cannabinoid-loaded microemulsion towards an improved stability and transdermal delivery. , 2021, International journal of pharmaceutics.

[29]  T. Wong,et al.  Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. , 2021, Ophthalmology.

[30]  Laureano Schofs,et al.  The antimicrobial effect behind Cannabis sativa , 2021, Pharmacology research & perspectives.

[31]  H. Dua,et al.  Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance , 2021, Eye.

[32]  A. L. Ruela,et al.  Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. , 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Ji-Peng Olivia Li,et al.  CannabinEYEds: The Endocannabinoid System as a Regulator of the Ocular Surface Nociception, Inflammatory Response, Neovascularization and Wound Healing , 2020, Journal of clinical medicine.

[34]  R. Dana,et al.  Defining Dry Eye from a Clinical Perspective , 2020, International journal of molecular sciences.

[35]  S. Majumdar,et al.  Effect of surfactant concentration and sterilization process on intraocular pressure–lowering activity of Δ9-tetrahydrocannabinol-valine-hemisuccinate (NB1111) nanoemulsions , 2020, Drug Delivery and Translational Research.

[36]  S. MacNeil,et al.  Corneal Infection Models: Tools to Investigate the Role of Biofilms in Bacterial Keratitis , 2020, Cells.

[37]  S. Kang,et al.  Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Li Yang,et al.  Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder , 2020, Neural Regeneration Research.

[39]  R. Ross,et al.  Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms. , 2020, Experimental eye research.

[40]  H. Rupasinghe,et al.  Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals , 2020, Molecules.

[41]  L. Rodríguez-Rodríguez,et al.  Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.

[42]  H. Danesh-Meyer,et al.  Cannabinoids and the eye. , 2020, Survey of ophthalmology.

[43]  H. Makarenkova,et al.  THC Regulates Tearing via Cannabinoid CB1 Receptors , 2020, Investigative ophthalmology & visual science.

[44]  Michael Ansong,et al.  Prodrugs and nanomicelles to overcome ocular barriers for drug penetration , 2020, Expert opinion on drug metabolism & toxicology.

[45]  I. Greenwood,et al.  Cyclic AMP-Dependent Regulation of Kv7 Voltage-Gated Potassium Channels , 2020, Frontiers in Physiology.

[46]  N. Garg,et al.  The Impact of Marijuana on the Cardiovascular System: A Review of the Most Common Cardiovascular Events Associated with Marijuana Use , 2020, Journal of clinical medicine.

[47]  F. Otero-Espinar,et al.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations , 2020, Pharmaceutics.

[48]  W. Hall,et al.  Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. , 2020, The International journal on drug policy.

[49]  R. Dana,et al.  Advances and limitations of drug delivery systems formulated as eye drops. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[50]  G. Thakur,et al.  Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation , 2020, Molecules.

[51]  S. Schwartz,et al.  Diabetic Retinopathy–An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes , 2019, Front. Endocrinol..

[52]  P. Lebranchu,et al.  Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema , 2019, Ocular immunology and inflammation.

[53]  M. Guida,et al.  Prevention of Pseudomonas aeruginosa Biofilm Formation on Soft Contact Lenses by Allium sativum Fermented Extract (BGE) and Cannabinol Oil Extract (CBD) , 2019, Antibiotics.

[54]  G. Yiu,et al.  Emerging Concepts in the Treatment of Diabetic Retinopathy , 2019, Current Diabetes Reports.

[55]  Rakan S. Al-Essa,et al.  Primary congenital glaucoma: An updated review , 2019, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

[56]  E. Sánchez-López,et al.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents , 2019, Pharmaceutics.

[57]  W. Guba,et al.  Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis , 2019, Molecules.

[58]  S. Majumdar,et al.  Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits , 2019, Translational vision science & technology.

[59]  M. Breunig,et al.  Causative glaucoma treatment: promising targets and delivery systems. , 2019, Drug discovery today.

[60]  M. Alonso,et al.  Oral Delivery of Biologics for Precision Medicine , 2019, Advanced materials.

[61]  S. Majumdar,et al.  Analog Derivatization of Cannabidiol for Improved Ocular Permeation. , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[62]  M. Elsohly,et al.  New trends in cannabis potency in USA and Europe during the last decade (2008–2017) , 2019, European Archives of Psychiatry and Clinical Neuroscience.

[63]  H. Bradshaw,et al.  Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure , 2018, Investigative ophthalmology & visual science.

[64]  E. Groce The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research , 2018, Journal of Medical Regulation.

[65]  K. Greish,et al.  Synthetic cannabinoids nano‐micelles for the management of triple negative breast cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[66]  H. Bradshaw,et al.  Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. , 2018, Prostaglandins & other lipid mediators.

[67]  V. Mishra,et al.  Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems , 2018, Pharmaceutics.

[68]  Shan C. Lin,et al.  Epidemiology of uveitis in a US population-based study , 2018, Journal of Ophthalmic Inflammation and Infection.

[69]  D. Pachito,et al.  Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews , 2018, Phytotherapy research : PTR.

[70]  Vikramaditya G. Yadav,et al.  A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery , 2018, Drug Delivery and Translational Research.

[71]  D. Thapa,et al.  The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation , 2018, Cannabis and cannabinoid research.

[72]  N. M. di Luca,et al.  Medical use of cannabis: Italian and European legislation. , 2018, European review for medical and pharmacological sciences.

[73]  J. Micó,et al.  Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[74]  S. Majumdar,et al.  Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations , 2017, AAPS PharmSciTech.

[75]  F. Atyabi,et al.  Application of carbon nanotubes as the carriers of the cannabinoid, 2‐arachidonoylglycerol: Towards a novel treatment strategy in colitis , 2017, Life sciences.

[76]  M. Alonso,et al.  Synthetic nanocarriers for the delivery of polynucleotides to the eye , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[77]  Farooq Ali Khan,et al.  Nanoemulsion: Concepts, development and applications in drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[78]  Amira M. El-Ganiny,et al.  Prevention of Bacterial Biofilm Formation on Soft Contact Lenses Using Natural Compounds , 2017, Journal of Ophthalmic Inflammation and Infection.

[79]  S. Majumdar,et al.  Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability , 2017, Investigative ophthalmology & visual science.

[80]  A. Mitra,et al.  Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[81]  B. Johnston,et al.  Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy , 2017, Neuropharmacology.

[82]  Sai Prachetan Balguri,et al.  Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[83]  F. Muñoz-Negrete,et al.  Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease. , 2016, Investigative ophthalmology & visual science.

[84]  Mei Wang,et al.  Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression , 2016, International journal of nanomedicine.

[85]  J. Toguri,et al.  Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain , 2016, Front. Pharmacol..

[86]  S. Panchal,et al.  Effect of potassium channel openers in acute and chronic models of glaucoma , 2016, Taiwan Journal of Ophthalmology.

[87]  Lina Yu,et al.  Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy , 2016, Advanced healthcare materials.

[88]  T. Tolker-Nielsen,et al.  Pseudomonas aeruginosa Biofilm Infections: Community Structure, Antimicrobial Tolerance and Immune Response. , 2015, Journal of molecular biology.

[89]  R. Beuerman,et al.  Corneal Biofilms: From Planktonic to Microcolony Formation in an Experimental Keratitis Infection with Pseudomonas Aeruginosa. , 2015, The ocular surface.

[90]  M. de la Fuente,et al.  Nanotherapies for the treatment of ocular diseases. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[91]  Eneida Pérez Candelaria,et al.  Corneal ulcers in contact lens wearers , 2015 .

[92]  K. Greish,et al.  Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model , 2015, Journal of drug targeting.

[93]  M. Gilmore,et al.  Biofilms in Infections of the Eye , 2015, Pathogens.

[94]  Lídia M D Gonçalves,et al.  Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids , 2015, Journal of Nanoparticle Research.

[95]  Leopold Schmetterer,et al.  Pharmacotherapy of glaucoma. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[96]  L. Martin-Banderas,et al.  Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. , 2014, Colloids and surfaces. B, Biointerfaces.

[97]  R. Laprairie,et al.  Anti‐inflammatory effects of cannabinoid CB2 receptor activation in endotoxin‐induced uveitis , 2014, British journal of pharmacology.

[98]  Ruchira Singh,et al.  CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons , 2013, Neuroscience Letters.

[99]  S. Sharma,et al.  Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. , 2013, Experimental eye research.

[100]  L. Marnett,et al.  Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury. , 2013, Cellular signalling.

[101]  M. A. Holgado,et al.  Development and Validation of an RP-HPLC Method for CB13 Evaluation in Several PLGA Nanoparticle Systems , 2012, TheScientificWorldJournal.

[102]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[103]  H. Quigley Glaucoma , 2011, The Lancet.

[104]  Yolanda Diebold,et al.  Applications of nanoparticles in ophthalmology , 2010, Progress in Retinal and Eye Research.

[105]  Justine R. Smith,et al.  Education in the ophthalmic discipline of uveitis. , 2008, American journal of ophthalmology.

[106]  J. Forrester,et al.  Anti‐inflammatory property of the cannabinoid receptor‐2‐selective agonist JWH‐133 in a rodent model of autoimmune uveoretinitis , 2007, Journal of leukocyte biology.

[107]  Y. Khalifa,et al.  Neuroprotective and Intraocular Pressure-Lowering Effects of (–)Δ9-Tetrahydrocannabinol in a Rat Model of Glaucoma , 2007, Ophthalmic Research.

[108]  M. Zierhut,et al.  Adalimumab in the therapy of uveitis in childhood , 2006, British Journal of Ophthalmology.

[109]  R. Pertwee,et al.  Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study , 2006, Journal of glaucoma.

[110]  P. Shek,et al.  Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[111]  A. Zuardi History of cannabis as a medicine: a review. , 2006, Revista brasileira de psiquiatria.

[112]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[113]  Y. Khalifa,et al.  Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.

[114]  S. Kingman Glaucoma is second leading cause of blindness globally. , 2004, Bulletin of the World Health Organization.

[115]  B. Godin,et al.  Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[116]  R. Caldwell,et al.  Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. , 2003, The American journal of pathology.

[117]  P. Foster,et al.  The definition and classification of glaucoma in prevalence surveys , 2002, The British journal of ophthalmology.

[118]  G. Gessa,et al.  The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies , 2001, The European journal of neuroscience.

[119]  Loftssona,et al.  Cyclodextrins in ophthalmic drug delivery. , 1999, Advanced drug delivery reviews.

[120]  J. H. Liu,et al.  Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids. , 1987, Archives of ophthalmology.

[121]  R. W. Wood,et al.  Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit , 1985 .

[122]  K. Green,et al.  Multiple-Drop Study of Topically Applied 1% Δ9-Tetrahydrocannabinol in Human Eyes , 1983 .

[123]  J. Tiedeman,et al.  Effect of synthetic cannabinoids on elevated intraocular pressure. , 1981, Ophthalmology.

[124]  W. J. Crawford,et al.  Effect of marihuana on intraocular and blood pressure in glaucoma. , 1980, Ophthalmology.

[125]  M. Luntz Congenital, infantile, and juvenile glaucoma. , 1979, Ophthalmology.

[126]  K. Green,et al.  A comparison of topical cannabinoids on intraocular pressure. , 1978, Experimental eye research.

[127]  J. Gregg,et al.  Effect of Delta‐9-Tetrahydrocannabinol on Intraocular Pressure in Humans , 1977, Southern medical journal.

[128]  S. Cohen,et al.  THE 94‐DAY CANNABIS STUDY , 1976, Annals of the New York Academy of Sciences.

[129]  R. Hepler,et al.  Marihuana smoking and intraocular pressure. , 1971, JAMA.

[130]  C. Baudouin,et al.  [Primary open-angle glaucoma]. , 2018, La Revue de medecine interne.

[131]  M. Jamal,et al.  Bacterial biofilm and associated infections. , 2018, Journal of the Chinese Medical Association : JCMA.

[132]  S. Doktorovová,et al.  Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular delivery , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[133]  P. Lehoang The gold standard of noninfectious uveitis: corticosteroids. , 2012, Developments in ophthalmology.

[134]  S. Pinar-Sueiro,et al.  Aplicaciones de los cannabinoides en glaucoma , 2011 .

[135]  E. Vecino,et al.  Cannabinoid applications in glaucoma , 2011 .

[136]  L. M. Calvo Hernández,et al.  [Uveitis: a challenge for internist]. , 2008, Anales de Medicina Interna.

[137]  J. Winston,et al.  Causes of Uveitis in the General Practice of Ophthalmology , 1996 .

[138]  S. Almog,et al.  A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. , 1992, Ophthalmic research.

[139]  M. Elsohly,et al.  Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. , 1984, Current eye research.

[140]  K. Green,et al.  Intraocular pressure following systemic administration of cannabinoids. , 1982, Current eye research.

[141]  R. Mechoulam,et al.  Marijuana ; chemistry, pharmacology, metabolism and clinical effects , 1973 .